Pharma Stock Under Rs 30: Sudarshan Pharma Industries reports stellar results, PAT jumps 68% in H1FY26

DSIJ Intelligence-1 / 23 Oct 2025/ Categories: Multibaggers, Penny Stocks, Trending

Pharma Stock Under Rs 30: Sudarshan Pharma Industries reports stellar results, PAT jumps 68% in H1FY26

The stock is up by 9.40 per cent from its 52-week low of Rs 24.69 per share and has given multibagger returns of over 260 per cent in 2 years.

On Thursday, shares of Sudarshan Pharma Industries Ltd gained 1.31 per cent to Rs 27 per share from its previous closing of Rs 26.65 per share. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 24.69 per share.

Also Read: FMCG Stock at All-Time High: Krishival Foods Ltd’s Board Approves Fundraising via Rights Issue

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East and North Africa.

Hunt for the next peak performer! DSIJ's multibagger Pick identifies high-risk, high-reward stocks with potential to triple BSE 500 returns in 3–5 years. Download Service Note

According to the Quarterly Results, the net sales increased by 16 per cent to Rs 168.87 crore in Q2FY26 compared to Q2FY25. The company reported a net profit of Rs 3.87 crore in Q2FY26. For half-yearly results, the net sales increased by 38 per cent to Rs 314.13 crore and net profit increased by 68 per cent to Rs 7.83 crore in H1FY26 compared to H1FY25. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24.

The company also successfully passed a special resolution on August 11, 2025, to raise funds to Rs 1,500 crore through various securities, subsequently receiving in-principle approval from BSE for the issuance of FCCBs up to USD 35 million. Furthermore, SPIL achieved a favorable litigation award in Dubai against Regans International DMCC and others, receiving a partial payment of over Rs 2.04 crore out of the total awarded amount of approximately Rs 9.19 crore and completed the acquisition of Cibachem General Trading LLC in Dubai and entered an agreement to acquire an API manufacturing facility from Sriglen Lifesciences Private Limited for Rs 25.05 crore.

The company has a market cap of Rs 650 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years. In September 2025, FIIs bought 31,44,000 shares and increased their stake by 20.79 per cent compared to June 2025. The stock is up by 9.40 per cent from its 52-week low of Rs 24.69 per share and has given multibagger returns of over 260 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.